ERBB2 and breast carcinoma: However, for HER-2 positive patients given the combination treatment, overall survival (OS) and time to progression (TTP), marking the time between randomization and progression of breast cancer or death, could be predicted by the metabolic profiles of sera taken at nine weeks.